Abstracts tagged "Outcome measures"

Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Bente Glintborg^1,2, Bjorn Gudbjornsson^3,4, Niels Steen Krogh⁵, Emina Omerovic², Natalia Manilo⁶, Mette Holland-Fischer⁷, Hanne M. Lindegaard⁸, Anne Gitte Loft⁹, Henrik Nordin¹⁰, Laura Johnsen¹¹, Sussi Flejsborg Oeftiger¹², Annette Hansen¹³, Claus Rasmussen¹⁴, Gerdur Grondal¹⁵, Árni Jón Geirsson¹⁶ and Merete Lund Hetland^1,2,17, ¹The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ³Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ¹⁰Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹¹Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, ¹²Department of Rheumatology, Køge Hospital, Køge, East Timor, ¹³Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ¹⁴Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹⁵Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
Abstract Number: 1979 • 2013 ACR/ARHP Annual Meeting
Occupational Balance Questionnaire: From People’s Perspectives To A Patient Reported Outcome
Mona Dür¹, Gunter Steiner², Michaela Stoffer³, Alexandra Kautzky-Willer⁴, Veronika Fialka-Moser⁵, Clemens Dejaco⁶, Birgit Prodinger⁷, Alexa Binder⁸, Josef S. Smolen^9,10 and Tanja A. Stamm¹¹, ¹Internal Medicine III Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Internal Medicine III, division of rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Internal Medicine III, Division of Diabetology, Medical University of Vienna, Vienna, Austria, ⁵Physical Medicine and Rehabilitation, Medical University of Vienna, Vienna, Austria, ⁶Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, ⁷ICF Research Branch, Swiss Paraplegic Group, Nottwil, Switzerland, Notwill, Switzerland, ⁸Occupational therapy, Hospital Goettlicher Heiland, Vienna, Austria, ⁹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁰Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹¹Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Occupational balance is one of the foundations on which occupational therapy is based. Occupational balance is defined diversely and mainly derived from the perspective…
Abstract Number: 191 • 2013 ACR/ARHP Annual Meeting
Does Specific Joint Involvement In Rheumatoid Arthritis Patients Predict Patient Reported Outcomes? Implications For Clinical Practice
Regan Arendse¹, William G. Bensen², Andrew Chow³, Jude F. Rodrigues⁴, Sanjay Dixit⁵, Dalton E. Sholter⁶, Philip Baer⁷, Milton F. Baker⁸, Denis Choquette⁹, Isabelle Fortin¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Susan M. Otawa¹⁴, May Shawi¹⁵ and Allen J. Lehman¹⁴, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatology, Windsor, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷Private Practice, Scarborough, ON, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹¹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Assessment of functional (dis)ability in rheumatoid arthritis (RA) is subject to patient judgment when appraising their ability to do daily activities. The aim of…
Abstract Number: 1881 • 2013 ACR/ARHP Annual Meeting
HLA-DRB1 Rheumatoid Arthritis Susceptibility Amino Acids Define Haplotypes Associated With Radiological Outcome
Sebastien Viatte¹, Annie Yarwood², Buhm Han^3,4, Soumya Raychaudhuri³, Deborah P. M. Symmons⁵, Jane Worthington^6,7 and Anne Barton^8,9, ¹Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, The University of Manchester and Rheumatoid Arthritis Consortium for Immunochip (RACI), International Consortium, United Kingdom, ⁷Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁹NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a systematic autoimmune disease caused by the interplay between environmental and genetic risk factors. The major genetic determinants of RA…
Abstract Number: 109 • 2013 ACR/ARHP Annual Meeting
Comparison Of Characteristics In Rheumatoid Arthritis Between International and National Databases In Europe: A Systematic Literature Review
E. Gvozdenovic¹, R. Koevoets¹, J. Langenhoff², C.F. Allaart¹ and R. Landewe³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: RA (Rheumatoid Arthritis) cohorts and registers are established for daily practice in clinical care. There are still differences between registries in disease activity and…
Abstract Number: 1791 • 2013 ACR/ARHP Annual Meeting
Reaching The Target Of Low Disease Activity At 6 Months Predicts Better Long-Term Functional Outcome In Patients With Early Rheumatoid Arthritis
Pooneh Akhavan¹, Bindee Kuriya², Edward C. Keystone^3,4, Juan Xiong⁵, Janet E. Pope⁶, Gilles Boire⁷, Diane Tin⁸, Boulos Haraoui⁹, Carol A. Hitchon¹⁰ and Vivian P. Bykerk^11,12, ¹Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶St Joseph Health Care, London, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ¹⁰Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ¹²Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Current clinical practice guidelines recommend remission, and if not possible, low disease activity (LDA) as the treatment target in rheumatoid arthritis (RA). Patients should…
Abstract Number: 2885 • 2013 ACR/ARHP Annual Meeting
Erosions and Sclerosis, But Not Squaring, Predict The Development Of New Syndesmophytes: A 12-Year Longitudinal Analysis (OASIS)
Sofia Ramiro¹, A.M. van Tubergen², Désirée van der Heijde³, Carmen Stolwijk⁴, Maxime Dougados⁵, Filip Van den Bosch⁶ and Robert Landewé⁷, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands
Background/Purpose: Erosions, sclerosis and squaring are included in the modified Stoke Ankylosing Spondylitis (AS) Spine Score (mSASSS). However, their value in predicting the development of…
Abstract Number: 1684 • 2013 ACR/ARHP Annual Meeting
Early Combination Immunosuppression and Serial Non-Invasive Imaging Improves Outcome In Takayasu Arteritis
Taryn Youngstein¹, Michael Quinn¹, James Peters¹ and Justin C. Mason², ¹Rheumatology Unit, Hammersmith Hospital, Imperial College London, London, United Kingdom, ²Rheumatology and Vascular Sciences, Hammersmith Hospital, Imperial College London, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) affects the aorta and its branches, pre-disposing to stenoses and aneurysmal dilatation. While morbidity remains high, evidence for efficacy of immunosuppressive…
Abstract Number: 2837 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity Leads To More Damage In The Early Phases Of Ankylosing Spondylitis: 12-Year Data From The OASIS Cohort
Sofia Ramiro¹, A.M. van Tubergen², Désirée van der Heijde³, Carmen Stolwijk⁴, Maxime Dougados⁵, Filip Van den Bosch⁶ and Robert Landewé⁷, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands
Background/Purpose: For years, it was unclear if inflammation and radiographic progression were related in ankylosing spondylitis (AS), but studies were only of short follow-up and…
Abstract Number: 1662 • 2013 ACR/ARHP Annual Meeting
Developing Guideline For Polymyalgia Rheumatica: Prioritisation Of Outcome Measures – Perspective Of Patients, General Practitioners and Rheumatologists
Yogesh Singh¹, Christian Dejaco^2,3, Sarah Mackie⁴, Daniel Ching⁵, Artur Bachta⁶, Ajesh Maharaj⁷, Alexandre Wagner⁸, Manuela Lima⁹, David Jayne¹⁰, Kevin Barraclough¹¹, Christian D Mallen¹², Stephen P. Merry¹³, Jane Hollywood¹⁴, Madeline Whitlock¹⁵, Kate Gilbert¹⁶, Pamela Hildreth¹⁶, Jennifer Nott¹⁶, Hannah Padbury¹⁶, Jean Miller¹⁶, Lorna Neill¹⁶, David Tronnier¹⁷, Pablo Perel¹⁸, Andrew Hutchings¹⁹, Dario Camellino²⁰, Steven E. Carsons²¹, William Docken²², Christina Duftner²³, Andy Abril²⁴, Robert F. Spiera²⁵, Colin T. Pease²⁶, Andreas P. Diamantopoulos²⁷, Frank Buttgereit²⁸, Peter V. Balint²⁹, Elisabeth Nordborg³⁰, Lina Bianconi³¹, Billy Fashanu¹⁵, Shunsuke Mori³², Víctor M. Martínez-Taboada³³, Maria C. Cid³⁴, Wolfgang A. Schmidt³⁵, Marco A. Cimmino³⁶, Michael Schirmer³⁷, Carlo Salvarani³⁸, Eric L. Matteson³⁹ and Bhaskar Dasgupta⁴⁰, ¹Rheumatology, Southend university hospital, Westcliff-on-sea, United Kingdom, ²Rheumatology and Immunology, Medical University Graz, Graz, Austria, ³Department of Rheumatology and Immunology, Medical University Graz, Graz A-8036, Austria, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁵Timaru Hospital, Timaru, New Zealand, ⁶Military Medical Institute, Warsaw, Poland, ⁷Prince Mshiyeni Memorial Hospital, Durban, South Africa, ⁸Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁹Universidade dos Açores, Azores, Portugal, ¹⁰Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ¹¹Hoyland House General Practice, Painswick, United Kingdom, ¹²Arthritis Research UK Primary Care Centre, University of Keele, Keele, United Kingdom, ¹³Family Medicine, Mayo Clinic, Rochester, MN, ¹⁴Rheumatology, Southend Hospital, Southend, United Kingdom, ¹⁵Southend University Hospital, Southend, United Kingdom, ¹⁶PMRGCAUK, Southend, United Kingdom, ¹⁷patients' representative, Rochester, MN, ¹⁸London School of Hygiene & Tropical Medicine, London, United Kingdom, ¹⁹Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ²⁰Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy, ²¹Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ²²Brigham Orth & Arthritis Center, Chestnut Hill, MA, ²³Internal Medicine, Hopital Kufstein, Kufstein, Austria, ²⁴Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ²⁵Rheumatology, Hospital for Special Surgery, New York, NY, ²⁶Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²⁷Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²⁸Charité - Universitätsmedizin Berlin, Berlin, Germany, ²⁹Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ³⁰Sahlgenska University Hospital, Goteborg, Sweden, ³¹Ambulatorio Medicina Generale, Bibbiano, Italy, ³²Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan, ³³Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, ³⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³⁷Internal medicine, Innsbruck Medical University, Innsbruck, Austria, ³⁸Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ³⁹Rheumatology, Mayo Clinic, Rochester, MN, ⁴⁰Southend University Hospital, Essex, United Kingdom
Background/Purpose: To explore similarities and differences between rheumatologists (rheum), general practitioners (GP) and patients (pt) regarding the relevance of outcome parameters in polymyalgia rheumatica (PMR).Methods:…
Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting
Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia
John S. Sampalis^1,2, Mary-Ann Fitzcharles³, Peter A. Ste-Marie⁴, Emmanouil Rampakakis^1,2 and Yoram Shir⁴, ¹JSS Medical Research, Montreal, QC, Canada, ²Jewish General Hospital, McGill University, Montreal, QC, Canada, ³Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…
Abstract Number: 1624 • 2013 ACR/ARHP Annual Meeting
Lupus Risk Alleles With High Ethnic Variability Worldwide Are Associated With Renal Disease In Hispanic Patients
Belinda Waltman¹, Kimberly E. Taylor², Joanne Nititham³ and Lindsey A. Criswell³, ¹Department of Medicine, University of California, San Francisco, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects minority patients. Non-European ancestry is associated with more severe disease, and conversely, European ancestry is associated with a…
Abstract Number: 2792 • 2013 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures
Julia G. Harris^1,2, Esi Morgan DeWitt³, Ronald M. Laxer^4,5, Stacy P. Ardoin⁶, Beth S. Gottlieb⁷, Judyann C. Olson^1,2, Murray H. Passo⁸, Jennifer E. Weiss⁹, Daniel J. Lovell¹⁰, Tzielan C. Lee¹¹, Sheetal S. Vora^12,13, Nancy Griffin¹⁴, Jason A. Stock¹⁵, Lynn M. Darbie¹⁴ and Catherine A. Bingham¹⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁷Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁸Pediatrics, Medical University of South Carolina, Charleston, SC, ⁹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²University of North Carolina Chapel Hill, Chapel Hill, NC, ¹³Levine Children's Hospital and Carolinas Medical Center, Charlotte, NC, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning network designed to improve outcomes of juvenile idiopathic arthritis (JIA) care. Teams…
Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience
Proton Rahman¹, Majed M. Khraishi², William Bensen³, John T. Kelsall⁴, Brian D. Hanna⁵, Craig Watts⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, May Shawi⁸, Susan M. Otawa⁹ and Allen J. Lehman⁹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Nexus Clinical Research, St John's, NF, Canada, ³St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Rheumatology, McMaster University, Ontario, Kitchener, ON, Canada, ⁶Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
Abstract Number: 2558 • 2012 ACR/ARHP Annual Meeting
Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry
Bente Glintborg¹, Mikkel Østergaard², Niels Steen Krogh³, Martin Dehn Andersen⁴, Ulrik Tarp⁴, Anne Gitte Loft⁴, Hanne M. Lindegaard⁵, Mette Holland-Fischer⁶, Henrik Nordin⁴, Dorte Vendelbo Jensen⁴ and Merete L. Hetland², ¹Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Treatment with tumor-necrosis-factor-alpha inhibitors (TNFi) has improved the outcome in patients with psoriatic arthritis (PsA) who have failed treatment with synthetic disease modifying antirheumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.